| Issue |
Section |
Title |
File |
| Vol 10, No 3 (2020) |
ORIGINAL REPORTS |
The efficacy and safety of nusinersen within the expanded access program in Russia |
(Rus)
|
| Vol 12, No 1 (2022) |
ORIGINAL REPORTS |
Experience of using gene replacement therapy with Zolgensma® (onasemnogene abeparvovec) in real clinical practice in Russia |
(Rus)
(Eng)
|
| Vol 12, No 2 (2022) |
LECTURES AND REVIEWS |
The concept of “ambulatory” and “non-ambulatory” in patients with Duchenne muscular dystrophy: definitions and criteria |
(Rus)
|
| Vol 12, No 2 (2022) |
ORIGINAL REPORTS |
Proximal spinal muscular atrophy 5q in the Republic of North Ossetia – Alania: population-genetic features, diagnostic problems and treatment prospects |
(Rus)
|
| Vol 13, No 2 (2023) |
LECTURES AND REVIEWS |
Consensus concept of modern effective therapy for Duchenne muscular dystrophy |
(Rus)
|
| Vol 13, No 4 (2023) |
CLINICAL DISCUSSION |
Modern methods of therapy of Duchenne muscular dystrophy: literature review with a clinical case |
(Rus)
|
| Vol 13, No 4 (2023) |
CLINICAL DISCUSSION |
A clinical case of severe aromatic L-amino acid decarboxylase deficiency |
(Rus)
|
| Vol 14, No 1 (2024) |
CLINICAL DISCUSSION |
Approaches to pathogenetic therapy of spinal muscular atrophy in children and newborns |
(Rus)
|
| Vol 14, No 4 (2024) |
LECTURES AND REVIEWS |
Functional class criteria identification in patients with spinal muscular atrophy 5q |
(Rus)
|
| Vol 15, No 1 (2025) |
ORIGINAL REPORTS |
Assessment of social emotional, cognitive and communicative development and adaptive behavior in children with spinal muscular atrophy 5q |
(Rus)
|
